US20170320025A1 - Methods for culturing and analyzing cells - Google Patents

Methods for culturing and analyzing cells Download PDF

Info

Publication number
US20170320025A1
US20170320025A1 US15/463,472 US201715463472A US2017320025A1 US 20170320025 A1 US20170320025 A1 US 20170320025A1 US 201715463472 A US201715463472 A US 201715463472A US 2017320025 A1 US2017320025 A1 US 2017320025A1
Authority
US
United States
Prior art keywords
droplet
sample
cells
droplets
wrapped
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/463,472
Inventor
Mark Davies
Tara Dalton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stokes Bio Ltd
Original Assignee
Stokes Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/366,524 external-priority patent/US7622076B2/en
Priority claimed from US12/683,882 external-priority patent/US8968659B2/en
Application filed by Stokes Bio Ltd filed Critical Stokes Bio Ltd
Priority to US15/463,472 priority Critical patent/US20170320025A1/en
Publication of US20170320025A1 publication Critical patent/US20170320025A1/en
Assigned to STOKES BIO LTD. reassignment STOKES BIO LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DALTON, TARA, DAVIES, MARK
Priority to US16/155,411 priority patent/US10967338B2/en
Priority to US17/197,177 priority patent/US11964244B2/en
Priority to US18/615,437 priority patent/US20240226823A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01FMIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F25/00Flow mixers; Mixers for falling materials, e.g. solid particles
    • B01F25/10Mixing by creating a vortex flow, e.g. by tangential introduction of flow components
    • B01F5/0057
    • B01F13/0059
    • B01F13/0071
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01FMIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F33/00Other mixers; Mixing plants; Combinations of mixers
    • B01F33/30Micromixers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01FMIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F33/00Other mixers; Mixing plants; Combinations of mixers
    • B01F33/30Micromixers
    • B01F33/302Micromixers the materials to be mixed flowing in the form of droplets
    • B01F33/3021Micromixers the materials to be mixed flowing in the form of droplets the components to be mixed being combined in a single independent droplet, e.g. these droplets being divided by a non-miscible fluid or consisting of independent droplets
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502769Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by multiphase flow arrangements
    • B01L3/502784Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by multiphase flow arrangements specially adapted for droplet or plug flow, e.g. digital microfluidics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L7/00Heating or cooling apparatus; Heat insulating devices
    • B01L7/52Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
    • B01L7/525Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples with physical movement of samples between temperature zones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/08Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a stream of discrete samples flowing along a tube system, e.g. flow injection analysis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06Fluid handling related problems
    • B01L2200/0636Focussing flows, e.g. to laminate flows
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06Fluid handling related problems
    • B01L2200/0673Handling of plugs of fluid surrounded by immiscible fluid
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/08Geometry, shape and general structure
    • B01L2300/0809Geometry, shape and general structure rectangular shaped
    • B01L2300/0816Cards, e.g. flat sample carriers usually with flow in two horizontal directions
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/08Geometry, shape and general structure
    • B01L2300/0861Configuration of multiple channels and/or chambers in a single devices
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/08Geometry, shape and general structure
    • B01L2300/0861Configuration of multiple channels and/or chambers in a single devices
    • B01L2300/087Multiple sequential chambers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/18Means for temperature control
    • B01L2300/1838Means for temperature control using fluid heat transfer medium
    • B01L2300/185Means for temperature control using fluid heat transfer medium using a liquid as fluid
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00Moving or stopping fluids
    • B01L2400/04Moving fluids with specific forces or mechanical means
    • B01L2400/0403Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0409Moving fluids with specific forces or mechanical means specific forces centrifugal forces
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00Moving or stopping fluids
    • B01L2400/04Moving fluids with specific forces or mechanical means
    • B01L2400/0475Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
    • B01L2400/0487Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N2035/00465Separating and mixing arrangements
    • G01N2035/00514Stationary mixing elements
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/10Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
    • G01N35/1095Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices for supplying the samples to flow-through analysers

Definitions

  • the present invention generally relates to methods for culturing and analyzing cells using liquid bridges.
  • Use of those therapies has revealed substantial differences in therapeutic response among individual. Any given drug may be therapeutic in some individuals while being ineffective in others. Further, a drug may produce adverse effects in certain individuals whereas others do not experience the same adverse reaction to the drug. Recognition of differences in drug response among individual is an important step towards optimizing therapy.
  • a problem with current approaches in drug therapy is that those therapies are designed for treatment of large patient populations as groups, irrespective of the potential for individual based differences in drug response. This approach is utilized due to costs and time associated with producing numerous cultures of an individual's cells, which is required for screening many different drugs as potential agents for effective disease treatment for a particular individual. This problem is particularly acute in the field of cancer therapy, in which tumors have qualities specific to individuals and individuals respond very differently to the same chemotherapeutic agent.
  • the present invention provides improved methods cell culturing and drug screening.
  • the invention involves using liquid bridges to produce droplets having at least one cell.
  • Liquid bridges are used to produce sample droplets that contain reaction components for rapid analysis of small sample volumes.
  • Liquid bridges allow the formation of sample droplets through the interaction of immiscible fluids.
  • the droplets may be dispensed into individual vessels for culturing of the cells or mixed with drugs to analyze the affect of the drug on the cell.
  • Use of liquid bridges provides for an automated system with high throughput for preparing cell cultures and for analyzing affect of drugs on cells.
  • the invention provides significant improvements in speed and cost associated with culturing and/or analyzing cells.
  • methods of the invention are used for high throughput fom 1 ation of droplets wrapped in an immiscible carrier fluid, in which the droplets contain at least one cell.
  • the droplets may then be dispensed and the cells are either cultured in the droplets or the droplets are burst and the cells are cultured in the vessel to which they are dispensed.
  • Droplets may be generated in numerous ways, although a preferred method is using liquid bridges.
  • One method of generating a sample droplet including at least one cell involves dipping an open ended channel into the first vessel to produce a sample droplet including at least one cell.
  • Another method of generating the sample droplet involves flowing a sample fluid including the plurality of cells to a liquid bridge, in which the liquid bridge segments the sample fluid to produce the wrapped sample droplets.
  • the sample droplets Prior to dispensing, the sample droplets may be mixed with cell culture media to produce a mixed wrapped droplet. Droplet mixing may be accomplished by flowing the sample droplets to a liquid bridge to mix with droplets of cell culture media to produce the mixed wrapped droplet. The sample droplets and the cell culture droplets may flow through a same channel, and flow may be used to cause the droplets to mix at the liquid bridge to form the mixed wrapped droplet. Alternatively, the sample droplets and the cell culture media droplets may flow through different channels and meet for mixing at the liquid bridge.
  • Methods of the invention involve dispensing the sample droplets to vessels for culturing.
  • the cells are dispensed to individual wells of a well plate, e.g., 96 well or 384 well plate.
  • Dispensing may be accomplished by generating a siphoning effect, and then using the siphoning affect to dispense the droplets.
  • the droplets are dispensed without a substantial amount of carrier fluid.
  • Methods of the invention may be used to prepare any type of cell for culturing, such as mammalian cells, e.g., human cells.
  • the cells are obtained from a human tissue or body fluid.
  • the cells are obtained from a tumor.
  • the cells are brain cells or embryonic cells.
  • the starting mixture of cells may be either homogeneous (i.e., a mixture including all the same type of cells) or heterogeneous (i.e., a mixture including a plurality of different types of cells).
  • Another aspect of the invention provides methods for analyzing the affect of at least one agent on a cell or cellular component.
  • Those methods of the invention involve forming a droplet wrapped in an immiscible carrier fluid, in which the droplet includes at least one cell or cellular component and at least one agent, and analyzing the wrapped droplet to determine the affect of the agent on the cell or cellular component. Analyzing of the cells may occur while the wrapped droplets are flowing through a channel. Alternatively, the droplets may be dispensed to a vessel, such as individual wells of a well plate, prior to analysis. In certain embodiments, a liquid bridge is used to form the wrapped droplets. In certain embodiments, the cells are lysed prior to being analyzed.
  • Methods of the invention may be used to analyze affect of any agent, or combination of agents, on any cell or combination of cells.
  • the cell is a cancerous cell and the agent is an anti-cancer agent or a combination of anti-cancer agents.
  • different concentrations of the same agent are analyzed.
  • the present invention generally relates to methods for culturing and analyzing cells using liquid bridges. Certain aspects of the invention provide methods for culturing cells.
  • the starting mixture of cells may be either homogeneous (i.e., a mixture including all the same type of cells) or heterogeneous (i.e., a mixture including a plurality of different types of cells).
  • Methods of the invention involve generating sample droplets wrapped in an immiscible carrier fluid including at least one cell.
  • Wrapped droplet generation may be accomplished by numerous techniques.
  • the wrapped droplets may be formed, for example, by dipping an open ended tube into a vessel.
  • Exemplary sample acquisition devices are shown in McGuire et al. (U.S. patent application Ser. No. 12/468,367), the contents of which are incorporated by reference herein in their entirety. Parameters such as channel diameter, dipping time, and system flow, may be adjusted so that wrapped droplets are formed in which each droplet contains only a single cell.
  • a method for generating wrapped droplets involves using a liquid bridge.
  • the liquid bridge is used to segment a flow of sample fluid into individual wrapped droplets.
  • the droplets formed in a liquid bridge are enveloped in an immiscible carrier fluid.
  • a typical liquid bridge of the invention is formed by an inlet in communication with a chamber that is filled with a carrier fluid.
  • the carrier fluid is immiscible with sample fluid flowing through the inlet into the chamber.
  • the sample fluid expands until it is large enough to span a gap between the inlet and an outlet in communication with the chamber.
  • Droplet formation is accomplished by adjusting flow rate, resulting in formation of an unstable funicular bridge that subsequently ruptures from the inlet.
  • the sample droplet After rupturing from the inlet, the sample droplet enters the outlet, surrounded by the carrier fluid from the chamber. Further description of using liquid bridges for droplet formation is shown in Davies et al. (International patent publication number WO 2007/091228), the contents of which are incorporated by reference herein in their entirety. Because droplet formation is controlled by flow rate, the flow rate may be adjusted to ensure that droplets are formed in which each droplet contains only a single cell.
  • droplets are formed such that each droplet contains only a single cell.
  • Poisson statistics dictate the dilution requirements needed to ensure that each wrapped droplet contains only a single cell. For example, if, on average, each wrapped droplet is to contain only a single cell, about 1 ⁇ 3 of the droplets will be empty and contain no cell, about 1 ⁇ 3 will contain exactly one cell, and about 1 ⁇ 3 will contain two or more cells.
  • the droplet population may be enriched to maximize the fraction that started with a single cell.
  • the population of cells may be fluorescently tagged and thus it is possible to flow sort the wrapped droplets after droplet formation to enrich for those that are fluorescent rather than empty.
  • High-speed flow sorters such as the MoFlo (Beckman-Coulter, Inc., Fullerton, Calif.), are capable of sorting at rates in excess of 70,000 per second and can be used to enrich a population of wrapped droplets of the invention.
  • the sample droplets may be mixed with cell culture media prior to dispensing of the droplet to produce a mixed wrapped droplet including at least one cell and culture media.
  • Any device that is capable of mixing sample droplets to form mixed sample droplets wrapped in an immiscible carrier fluid may be used with methods of the invention.
  • An exemplary droplet mixing device is a liquid bridge. For droplet mixing in a liquid bridge, the sample droplet containing the cell flows to an inlet and enters a chamber that is filled with a carrier fluid. The carrier fluid is immiscible with the sample droplet. The sample droplet expands until it is large enough to span a gap between inlet and outlet ports.
  • Droplet mixing can be accomplished in many ways, for example, by adjusting flow rate or by introducing a droplet of cell culture media to the sample droplet from a second inlet, forming an unstable funicular bridge that subsequently ruptures from the inlet. After rupturing from the inlet, the mixed sample droplet enters the outlet, surrounded by the carrier fluid from the chamber. Further description of using liquid bridges for droplet mixing is shown in Davies et al. (International patent publication number WO 2007/091228).
  • sample droplets and the cell culture media droplets may flow through a same channel, and flow may be used to cause the droplets to mix at the liquid bridge to form the mixed wrapped droplet.
  • sample droplets and the cell culture media droplets may flow through different channels and meet for mixing at the liquid bridge.
  • the cells in the droplets are cultured.
  • the wrapped droplets may are dispensed to a vessel or vessels for culturing of the cells in the droplets.
  • the vessel is a well plate, e.g. 96 well or 384 well, and the droplets are dispensed to individual wells of the well plate.
  • Droplet dispensing may be accomplished in numerous ways.
  • a system is configured to produce a siphoning effect.
  • the siphoning effect refers to flow that is driven by a difference in hydrostatic pressure without any need for pumping.
  • the effect is produced by configuring a system such that a dispensing end or port is lower than a fluid surface at an acquisition point, e.g., a sample acquisition stage.
  • the system may include any number of additional components that are positioned at an intermediate point in the system. Those intermediate components may be higher or lower than the acquisition point as long as the dispensing end is lower than the fluid surface at the acquisition point.
  • the siphoning effect drives flow through the system and is used to dispense the droplets.
  • the siphoning allows for dispensing of individual intact sample droplets, and thus individual intact cells for culturing. Further description regarding systems driven by a siphoning effect is shown in Davies et al. (U.S. patent application Ser. No. 12/683,882, filed Jan. 7, 2010, and entitled “Sample Dispensing”), the contents of which are incorporated by references herein in their entirety.
  • the cells are cultured in the wrapped droplets.
  • Media exchange may be accomplished by re-acquiring the droplets into the liquid bridge system using a sample acquisition device such as one described in McGuire et al. (U.S. patent application Ser. No. 12/468,367, filed May 19, 2009, and entitled “Sampling Device With Immiscible Fluid Supply Tube in Counter-Flow Arrangement,” now U.S. Pat. No. 8,697,011), the content of which is incorporated by reference herein in its entirety.
  • the sample droplet is flowed to a liquid bridge where it is segmented, forming two droplets: a droplet of used culture media; and a droplet containing the cultured cells in a reduced volume of culture media.
  • Droplet segmentation is described for example in Davies et al. (U.S. patent application No. 2008/0277494), the content of which is incorporated by reference herein in its entirety.
  • the droplets are then flowed to a subsequent liquid bridge where a droplet of fresh cell culture media is introduced to the droplet containing the cell culture.
  • a droplet of fresh cell culture media is introduced to the droplet containing the cell culture.
  • old culture media is removed from the cell culture and the cell culture is provided with fresh media.
  • the droplet containing the cell culture is subsequently dispensed to a vessel for continued culturing or analysis and the droplet containing solely media is dispensed to waste. This process may be repeated as many times as necessary.
  • the droplets may be dispensed to a vessel as wrapped droplets that are subsequently ruptured in the vessel.
  • flow rate is used to ensure that a substantial portion of the carrier fluid is not dispensed into the collecting vessel.
  • the flow is controlled such that the dispensing port can be moved over a waste container to dispense the carrier fluid surrounding the droplets, and then moved over a collecting vessel to dispense the sample droplets. In this manner, a substantial a portion of the carrier fluid is not dispensed into the collecting vessel. Movement of the dispensing port is controlled by at least one robotics system.
  • Cells can be grown in suspension or adherent cultures. Some cells naturally live in suspension, without being attached to a surface, such as cells that exist in the bloodstream. There are also cell lines that have been modified to be able to survive in suspension cultures so that they can be grown to a higher density than adherent conditions would allow.
  • Adherent cells require a surface, such as tissue culture plastic or microcarrier, which may be coated with extracellular matrix components to increase adhesion properties and provide other signals needed for growth and differentiation. Most cells derived from solid tissues are adherent.
  • the droplets may contain a support matrix or microcarrier. The liquid bridge may be used to introduce the microcarrier to the droplet containing the cells.
  • the cells are cultured according to standard methods and protocols known to one of skill in the art. See for example, J. W. Pollard and J. M. Walker (Basic Cell Culture Protocols, 2nd ed.: Methods in Molecular Biology, Vol. 75, Humana Press, 1997); J. Davis (Basic Cell Culture: A Practical Approach, 2nd ed., Oxford University Press, 2002); S. Ozturk and W. Hu (Cell Culture Technology for Pharmaceutical and Cell-Based Therapies, CRC Press, 2005); A. Doyle and J. B. Griffiths (Cell and Tissue Culture for Medical Research, John Wiley & Sons, Ltd, 2000); A. Doyle, J. B.
  • the cells are mammalian cells, such as human cells or animal cells.
  • the cells are cells from a human tissue or body fluid.
  • a tissue is a mass of connected cells and/or extracellular matrix material, e.g. skin tissue, nasal passage tissue, CNS tissue, neural tissue, eye tissue, liver tissue, kidney tissue, placental tissue, mammary gland tissue, gastrointestinal tissue, musculoskeletal tissue, genitourinary tissue, bone marrow, and the like, derived from, for example, a human or other mammal and includes the connecting material and the liquid material in association with the cells and/or tissues.
  • a body fluid is a liquid material derived from, for example, a human or other mammal.
  • body fluids include, but are not limited to urine, sputum, stool, mucous, saliva, blood, plasma, serum, serum derivatives, bile, phlegm, sweat, amniotic fluid, mammary fluid, and cerebrospinal fluid (CSF), such as lumbar or ventricular CSF.
  • CSF cerebrospinal fluid
  • the cell may also be from a fine needle aspirate or biopsied tissue.
  • the cells are tumor cells.
  • the cells are brain cells or embryonic cells.
  • Another aspect of the invention provides methods for analyzing effect of at least one agent on a cell or cellular component.
  • Methods of the invention involve forming a droplet wrapped in an immiscible carrier fluid, in which the droplet includes at least one cell or cellular component and at least one agent, and analyzing the wrapped droplet to determine effect of the agent on the cell or cellular component.
  • Methods of the invention may be used to analyze effect of any agent, or combination of agents, on any cell or combination of cells.
  • the cells are mammalian cells, such as human cells or animal cells.
  • the cells are cells from a human tissue or body fluid.
  • the cells are tumor cells.
  • the starting mixture of cells may be either homogeneous (i.e., a mixture including all the same type of cells) or heterogeneous (i.e., a mixture including a plurality of different types of cells).
  • methods of the invention are used to analyze specific cellular components, such as a nucleolus, a nucleus, a ribosome, a vesicle, a rough endoplasmic reticulum, a Golgi apparatus, cytoskeleton, a smooth endoplasmic reticulum, a mitochondria, a vacuole, a cytoplasm, a lysosome, or centrioles within centrosome.
  • the cellular component is nucleic acid, such as DNA or RNA.
  • cell may be lysed by using a liquid bridge to introduce a droplet containing a lysing agent to the droplet containing the cell. Formation of the mixed droplet mixes the lysing agent with the cell, lysing the cell and releasing the internal cellular components for subsequent analysis.
  • the lysing agent may be a chemical agent, such as surfactants, solvents, or antibiotics.
  • Droplet generation may be accomplished as described above, and droplet generation may be controlled as described above to produce droplets that include only a single cell. Alternatively, droplets may be formed that include a plurality of cells.
  • the agent may be any agent or combination of agents. Exemplary agents are shown in The Merck Index (14th edition. Whitehouse Station, New Jersey, 2009), the contents of which are incorporated by reference herein in their entirety.
  • the agent is an anti-cancer agent.
  • Exemplary anti-cancer agents are shown in The Merck Index (14th edition. Whitehouse Station, New Jersey, 2009) and Dorr et al. (Cancer Chemotherapy Handbook, 2d edition, pages 15-34, Appleton & Lange, Connecticut, 1994), the contents of each of which are incorporated by reference herein in their entirety.
  • the anti-cancer agent is altretamine, asparaginase, bleomycin, capecitabine, carboplatin, carmustine, cladribine, cisplatin, cyclophosphamide, cytarabine, dacarbazine, actinomycin D, docetaxel, doxorubicin, imatinib, etoposide, fludarabine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, methotrexate, mitomycin, mitotane, mitoxantrone, paclitaxel, topotecan, vinblastine, vincristine, vinorelbine, or combination thereof.
  • different concentrations of the same agent is provided to different cells, thus providing an ability to determine an effective dosage level or a toxicity level of an agent.
  • An exemplary droplet device is a liquid bridge. Wrapped droplet formation using liquid bridges is described above.
  • the sample droplets and the agent droplets may flow through a same channel, and flow may be used to cause the droplets to mix at the liquid bridge to form the mixed wrapped droplet.
  • the sample droplets and the agent droplets may flow through different channels and meet for mixing at the liquid bridge.
  • the cell or cells in the mixed wrapped droplet are analyzed to determine the effect of the agent on the cell or cellular component in the droplet. Analyzing may be continuously, periodically or after a specific period of time. Analyzing involves monitoring characteristic analog outcome measures, which may include, but are not limited to: analog size, shape, density, color or opacity; changes in cell number; cell death or proliferation; changes in secreted materials such as cytokines, growth factors, hormones or extracellular matrix components; genetic markers that are up- or down-regulated during the culture period such as genes for receptors, cytokines, integrins, extracellular matrix molecules, or enzymes; and cell-surface molecules including integrins and receptors.
  • characteristic analog outcome measures may include, but are not limited to: analog size, shape, density, color or opacity; changes in cell number; cell death or proliferation; changes in secreted materials such as cytokines, growth factors, hormones or extracellular matrix components; genetic markers that are up- or down-regulated during the culture period such as genes for receptors
  • One method analyzing the cell or cells includes performing a cell viability and/or proliferative capacity assay. For example, Trypan blue is one of several stains recommended for use in dye exclusion procedures for viable cell counting. This method is based on the principle that Jive cells do not take up certain dyes, whereas dead cells do. Trypan blue is introduced to the cell or cells and the cells are observed for uptake of the stain. A hemocytometer may be used to observe the cell or cells. Methods for performing this assay are well known in the art.
  • RNA extraction and analysis by reverse transcriptase-polymerase chain reaction includes RNA extraction and analysis by reverse transcriptase-polymerase chain reaction (RT-PCR).
  • RT-PCR reverse transcriptase-polymerase chain reaction
  • Cells in the construct are lysed and total RNA extracted with TRIZOL (Life Technologies., Rockville, Md.). Equal amounts (1 ⁇ g) of total RNA are subjected to reverse transcription into cDNA at 42° C. for one hour with oligo (dt 18 ) primers.
  • the transcripts are then be amplified by RT-PCR.
  • Sample cDNA are also amplified for housekeeping genes such as rRNA subunit S14 for controls.
  • Another method for analyzing the cell or cells includes cytological-immunocytochemical analysis of cell products.
  • Cells are fixed and stained with either hematoxylin-eosin (H&E) or with monospecific antibodies. Immunostaining for the marker or product of interest is visualized using immunoperoxidase technique with a substrate such as diaminobenzidine which will yield a brownish color. Cell preparations are counterstained with 0.5% toluidine blue.
  • H&E hematoxylin-eosin
  • Another method for analyzing the cell or cells includes western blots.
  • Cells may be resuspended in lysis buffer containing protease inhibitors. Protein concentrations may be determined and total cell extracts may be electrophoresed on 7% SDS-polyacrylamide gel overlaid with stacking gel. The proteins are transferred from gel to nitrocellulose paper to immunolocalize the product using monospecific antibodies. To visualize the bands, the membrane blot may be exposed to BioMax Light Film (VWR, NJ).
  • VWR BioMax Light Film
  • Another method for analyzing the cell or cells includes determination of particular enzyme products. Enzymatic products may be assessed by serially diluting media samples and analyzing enzymatic activity using commercially available kits based on an enzyme linked immunoasssay.
  • ELISA assays Other methods of analyzing the cells include ELISA assays, or microarray technology.
  • Analyzing of the cells may occur while the wrapped droplets are flowing through a channel.
  • the mixed wrapped droplet may flow to a subsequent liquid bridge for an additional mixing step in which the mixed droplet mixes with a droplet of Trypan blue.
  • the droplet now containing the cell(s), agent, and Trypan blue is flowed to a detection device (such as a CCD camera) that images the cells in the droplets as the droplets are flowing through the channel.
  • the droplets may be dispensed to a second vessel prior to analysis.
  • Droplet dispensing may be accomplished as described above.
  • Exemplary vessels include plates (e.g., 96 well or 384 well plates), eppendorf tubes, vials, beakers, flasks, centrifuge tubes, capillary tubes, cryogenic vials, bags, cups, or containers.
  • the second vessel is a well plate and the droplets are dispensed into individual wells of the well plate, one droplet per well.
  • the droplet including the cell or cellular component is not mixed with an agent. Rather, the unmixed droplet is dispensed to at least one secondary vessel that already includes the agent. For example, droplets are dispensed to individual wells of a well plate in which each well of the plate already includes an agent or combination of agent. After dispensing, the cells are analyzed to assess the effect of the agent or combination of agents on the cell or cellular component.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Clinical Laboratory Science (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A system for analyzing a biological sample may include at least one sample acquisition stage comprising a sample acquisition device for acquiring the biological sample from a sample source; a droplet generator device for forming a droplet wrapped in an immiscible carrier fluid, wherein the wrapped droplet comprises at least the biological sample and a reagent, the droplet generator configured to receive the biological sample transferred from the sample acquisition device; a collection vessel for collecting the wrapped sample droplet from the droplet generator, the vessel configured to contain a carrier fluid for receiving and protecting the sample droplet; and an analysis system for analyzing the wrapped sample droplet and detecting products of a polymerase chain reaction.

Description

    RELATED APPLICATIONS
  • This application is a divisional application is U.S. patent application Ser. No. 12/732,769, filed Mar. 26, 2010, which is a continuation-in-part of U.S. patent application Ser. No. 12/683,882, filed Jan. 7, 2010 (now U.S. Pat. No. 8,968,659), which is a continuation-in-part of U.S. patent application Ser. No. 12/617,286, filed Nov. 12, 2009 (now abandoned), which is a continuation of U.S. patent application Ser. No. 11/366,524, filed Mar. 3, 2006 (now U.S. Pat. No. 7,622,076), which is a continuation of PCT/IE2004/000115 filed Sep. 6, 2004 and published in English (now expired), claiming the priorities of U.S. patent application Ser. Nos. 60/500,344 and 60/500,345, both filed on Sep. 5, 2003 (both now expired). The contents of each of these applications are incorporated by reference herein in their entirety.
  • FIELD OF THE INVENTION
  • The present invention generally relates to methods for culturing and analyzing cells using liquid bridges.
  • BACKGROUND
  • A broad range of therapies exist that may be used to treat patients afflicted with diseases, such as infections, cardiovascular disease, and neoplastic disease. Use of those therapies has revealed substantial differences in therapeutic response among individual. Any given drug may be therapeutic in some individuals while being ineffective in others. Further, a drug may produce adverse effects in certain individuals whereas others do not experience the same adverse reaction to the drug. Recognition of differences in drug response among individual is an important step towards optimizing therapy.
  • A problem with current approaches in drug therapy is that those therapies are designed for treatment of large patient populations as groups, irrespective of the potential for individual based differences in drug response. This approach is utilized due to costs and time associated with producing numerous cultures of an individual's cells, which is required for screening many different drugs as potential agents for effective disease treatment for a particular individual. This problem is particularly acute in the field of cancer therapy, in which tumors have qualities specific to individuals and individuals respond very differently to the same chemotherapeutic agent.
  • There is a need for methods that can rapidly and cost effectively culture and analyze an individual's cells so that personalized treatment protocols may be developed and implemented.
  • SUMMARY
  • The present invention provides improved methods cell culturing and drug screening. In general, the invention involves using liquid bridges to produce droplets having at least one cell. Liquid bridges are used to produce sample droplets that contain reaction components for rapid analysis of small sample volumes. Liquid bridges allow the formation of sample droplets through the interaction of immiscible fluids. The droplets may be dispensed into individual vessels for culturing of the cells or mixed with drugs to analyze the affect of the drug on the cell. Use of liquid bridges provides for an automated system with high throughput for preparing cell cultures and for analyzing affect of drugs on cells. Thus the invention provides significant improvements in speed and cost associated with culturing and/or analyzing cells.
  • In certain aspects, methods of the invention are used for high throughput fom1 ation of droplets wrapped in an immiscible carrier fluid, in which the droplets contain at least one cell. The droplets may then be dispensed and the cells are either cultured in the droplets or the droplets are burst and the cells are cultured in the vessel to which they are dispensed. Droplets may be generated in numerous ways, although a preferred method is using liquid bridges. One method of generating a sample droplet including at least one cell involves dipping an open ended channel into the first vessel to produce a sample droplet including at least one cell. Another method of generating the sample droplet involves flowing a sample fluid including the plurality of cells to a liquid bridge, in which the liquid bridge segments the sample fluid to produce the wrapped sample droplets.
  • Prior to dispensing, the sample droplets may be mixed with cell culture media to produce a mixed wrapped droplet. Droplet mixing may be accomplished by flowing the sample droplets to a liquid bridge to mix with droplets of cell culture media to produce the mixed wrapped droplet. The sample droplets and the cell culture droplets may flow through a same channel, and flow may be used to cause the droplets to mix at the liquid bridge to form the mixed wrapped droplet. Alternatively, the sample droplets and the cell culture media droplets may flow through different channels and meet for mixing at the liquid bridge.
  • Methods of the invention involve dispensing the sample droplets to vessels for culturing. In particular embodiments, the cells are dispensed to individual wells of a well plate, e.g., 96 well or 384 well plate. Dispensing may be accomplished by generating a siphoning effect, and then using the siphoning affect to dispense the droplets. In certain embodiments, the droplets are dispensed without a substantial amount of carrier fluid.
  • Methods of the invention may be used to prepare any type of cell for culturing, such as mammalian cells, e.g., human cells. In certain embodiments, the cells are obtained from a human tissue or body fluid. In particular embodiments, the cells are obtained from a tumor. In other embodiments, the cells are brain cells or embryonic cells. The starting mixture of cells may be either homogeneous (i.e., a mixture including all the same type of cells) or heterogeneous (i.e., a mixture including a plurality of different types of cells).
  • Another aspect of the invention provides methods for analyzing the affect of at least one agent on a cell or cellular component. Those methods of the invention involve forming a droplet wrapped in an immiscible carrier fluid, in which the droplet includes at least one cell or cellular component and at least one agent, and analyzing the wrapped droplet to determine the affect of the agent on the cell or cellular component. Analyzing of the cells may occur while the wrapped droplets are flowing through a channel. Alternatively, the droplets may be dispensed to a vessel, such as individual wells of a well plate, prior to analysis. In certain embodiments, a liquid bridge is used to form the wrapped droplets. In certain embodiments, the cells are lysed prior to being analyzed.
  • Methods of the invention may be used to analyze affect of any agent, or combination of agents, on any cell or combination of cells. In certain embodiments, the cell is a cancerous cell and the agent is an anti-cancer agent or a combination of anti-cancer agents. In other embodiments, different concentrations of the same agent are analyzed.
  • DETAILED DESCRIPTION
  • The present invention generally relates to methods for culturing and analyzing cells using liquid bridges. Certain aspects of the invention provide methods for culturing cells. The starting mixture of cells may be either homogeneous (i.e., a mixture including all the same type of cells) or heterogeneous (i.e., a mixture including a plurality of different types of cells). Methods of the invention involve generating sample droplets wrapped in an immiscible carrier fluid including at least one cell.
  • Wrapped droplet generation may be accomplished by numerous techniques. The wrapped droplets may be formed, for example, by dipping an open ended tube into a vessel. Exemplary sample acquisition devices are shown in McGuire et al. (U.S. patent application Ser. No. 12/468,367), the contents of which are incorporated by reference herein in their entirety. Parameters such as channel diameter, dipping time, and system flow, may be adjusted so that wrapped droplets are formed in which each droplet contains only a single cell.
  • Another method for generating wrapped droplets involves using a liquid bridge. The liquid bridge is used to segment a flow of sample fluid into individual wrapped droplets. The droplets formed in a liquid bridge are enveloped in an immiscible carrier fluid. A typical liquid bridge of the invention is formed by an inlet in communication with a chamber that is filled with a carrier fluid. The carrier fluid is immiscible with sample fluid flowing through the inlet into the chamber. The sample fluid expands until it is large enough to span a gap between the inlet and an outlet in communication with the chamber. Droplet formation is accomplished by adjusting flow rate, resulting in formation of an unstable funicular bridge that subsequently ruptures from the inlet. After rupturing from the inlet, the sample droplet enters the outlet, surrounded by the carrier fluid from the chamber. Further description of using liquid bridges for droplet formation is shown in Davies et al. (International patent publication number WO 2007/091228), the contents of which are incorporated by reference herein in their entirety. Because droplet formation is controlled by flow rate, the flow rate may be adjusted to ensure that droplets are formed in which each droplet contains only a single cell.
  • In certain embodiments, droplets are formed such that each droplet contains only a single cell. Poisson statistics dictate the dilution requirements needed to ensure that each wrapped droplet contains only a single cell. For example, if, on average, each wrapped droplet is to contain only a single cell, about ⅓ of the droplets will be empty and contain no cell, about ⅓ will contain exactly one cell, and about ⅓ will contain two or more cells.
  • The droplet population may be enriched to maximize the fraction that started with a single cell. For example, the population of cells may be fluorescently tagged and thus it is possible to flow sort the wrapped droplets after droplet formation to enrich for those that are fluorescent rather than empty. High-speed flow sorters, such as the MoFlo (Beckman-Coulter, Inc., Fullerton, Calif.), are capable of sorting at rates in excess of 70,000 per second and can be used to enrich a population of wrapped droplets of the invention. Similarly, it is possible to exploit other differences between empty and full wrapped droplets (e.g., buoyant density) to enrich a population of droplets. In order to enrich for droplets with one cell as opposed to several cells, it may be desirable to skew the Poisson distribution accordingly.
  • In certain embodiments, the sample droplets may be mixed with cell culture media prior to dispensing of the droplet to produce a mixed wrapped droplet including at least one cell and culture media. Any device that is capable of mixing sample droplets to form mixed sample droplets wrapped in an immiscible carrier fluid may be used with methods of the invention. An exemplary droplet mixing device is a liquid bridge. For droplet mixing in a liquid bridge, the sample droplet containing the cell flows to an inlet and enters a chamber that is filled with a carrier fluid. The carrier fluid is immiscible with the sample droplet. The sample droplet expands until it is large enough to span a gap between inlet and outlet ports. Droplet mixing can be accomplished in many ways, for example, by adjusting flow rate or by introducing a droplet of cell culture media to the sample droplet from a second inlet, forming an unstable funicular bridge that subsequently ruptures from the inlet. After rupturing from the inlet, the mixed sample droplet enters the outlet, surrounded by the carrier fluid from the chamber. Further description of using liquid bridges for droplet mixing is shown in Davies et al. (International patent publication number WO 2007/091228).
  • The sample droplets and the cell culture media droplets may flow through a same channel, and flow may be used to cause the droplets to mix at the liquid bridge to form the mixed wrapped droplet. Alternatively, the sample droplets and the cell culture media droplets may flow through different channels and meet for mixing at the liquid bridge.
  • After droplet generation, the cells in the droplets are cultured. In certain embodiments, the wrapped droplets may are dispensed to a vessel or vessels for culturing of the cells in the droplets. In particular embodiments, the vessel is a well plate, e.g. 96 well or 384 well, and the droplets are dispensed to individual wells of the well plate. Droplet dispensing may be accomplished in numerous ways. In certain embodiments, a system is configured to produce a siphoning effect. The siphoning effect refers to flow that is driven by a difference in hydrostatic pressure without any need for pumping. The effect is produced by configuring a system such that a dispensing end or port is lower than a fluid surface at an acquisition point, e.g., a sample acquisition stage. The system may include any number of additional components that are positioned at an intermediate point in the system. Those intermediate components may be higher or lower than the acquisition point as long as the dispensing end is lower than the fluid surface at the acquisition point.
  • The siphoning effect drives flow through the system and is used to dispense the droplets. The siphoning allows for dispensing of individual intact sample droplets, and thus individual intact cells for culturing. Further description regarding systems driven by a siphoning effect is shown in Davies et al. (U.S. patent application Ser. No. 12/683,882, filed Jan. 7, 2010, and entitled “Sample Dispensing”), the contents of which are incorporated by references herein in their entirety.
  • In certain embodiments, the cells are cultured in the wrapped droplets. Media exchange may be accomplished by re-acquiring the droplets into the liquid bridge system using a sample acquisition device such as one described in McGuire et al. (U.S. patent application Ser. No. 12/468,367, filed May 19, 2009, and entitled “Sampling Device With Immiscible Fluid Supply Tube in Counter-Flow Arrangement,” now U.S. Pat. No. 8,697,011), the content of which is incorporated by reference herein in its entirety.
  • Once the droplet has been acquired, the sample droplet is flowed to a liquid bridge where it is segmented, forming two droplets: a droplet of used culture media; and a droplet containing the cultured cells in a reduced volume of culture media. Droplet segmentation is described for example in Davies et al. (U.S. patent application No. 2008/0277494), the content of which is incorporated by reference herein in its entirety.
  • After segmentation, the droplets are then flowed to a subsequent liquid bridge where a droplet of fresh cell culture media is introduced to the droplet containing the cell culture. In this manner, old culture media is removed from the cell culture and the cell culture is provided with fresh media. The droplet containing the cell culture is subsequently dispensed to a vessel for continued culturing or analysis and the droplet containing solely media is dispensed to waste. This process may be repeated as many times as necessary.
  • In other embodiments, the droplets may be dispensed to a vessel as wrapped droplets that are subsequently ruptured in the vessel. In certain embodiments, it is advantageous to ensure that a substantial portion of the carrier fluid is not dispensed into the collecting vessel. In one manner, flow rate is used to ensure that a substantial portion of the carrier fluid is not dispensed into the collecting vessel. The flow is controlled such that the dispensing port can be moved over a waste container to dispense the carrier fluid surrounding the droplets, and then moved over a collecting vessel to dispense the sample droplets. In this manner, a substantial a portion of the carrier fluid is not dispensed into the collecting vessel. Movement of the dispensing port is controlled by at least one robotics system.
  • Cells can be grown in suspension or adherent cultures. Some cells naturally live in suspension, without being attached to a surface, such as cells that exist in the bloodstream. There are also cell lines that have been modified to be able to survive in suspension cultures so that they can be grown to a higher density than adherent conditions would allow. Adherent cells require a surface, such as tissue culture plastic or microcarrier, which may be coated with extracellular matrix components to increase adhesion properties and provide other signals needed for growth and differentiation. Most cells derived from solid tissues are adherent. Depending on the type of cells to be cultured, the droplets may contain a support matrix or microcarrier. The liquid bridge may be used to introduce the microcarrier to the droplet containing the cells.
  • Once dispensed, the cells are cultured according to standard methods and protocols known to one of skill in the art. See for example, J. W. Pollard and J. M. Walker (Basic Cell Culture Protocols, 2nd ed.: Methods in Molecular Biology, Vol. 75, Humana Press, 1997); J. Davis (Basic Cell Culture: A Practical Approach, 2nd ed., Oxford University Press, 2002); S. Ozturk and W. Hu (Cell Culture Technology for Pharmaceutical and Cell-Based Therapies, CRC Press, 2005); A. Doyle and J. B. Griffiths (Cell and Tissue Culture for Medical Research, John Wiley & Sons, Ltd, 2000); A. Doyle, J. B. Griffiths (Cell and Tissue Culture: Laboratory Procedures in Biotechnology, John Wiley & Sons, Ltd, 1998); R. Ian Freshney (Culture of Animal Cells: A Manual of Basic Techniques, 5th ed., John Wiley & Sons, 2005); G. Vunjak-Novakovic and R. I. Freshney (Culture of Cells for Tissue Engineering, John Wiley & Sons, 2006); and R. Pfragner and R. Freshney (Culture of Human Tumor Cells, John Wiley & Sons, 2003). The contents of each of the above is incorporated by reference herein in its entirety.
  • Methods of the invention may be used with any cells. In certain embodiments, the cells are mammalian cells, such as human cells or animal cells. In other embodiments, the cells are cells from a human tissue or body fluid. A tissue is a mass of connected cells and/or extracellular matrix material, e.g. skin tissue, nasal passage tissue, CNS tissue, neural tissue, eye tissue, liver tissue, kidney tissue, placental tissue, mammary gland tissue, gastrointestinal tissue, musculoskeletal tissue, genitourinary tissue, bone marrow, and the like, derived from, for example, a human or other mammal and includes the connecting material and the liquid material in association with the cells and/or tissues. A body fluid is a liquid material derived from, for example, a human or other mammal. Such body fluids include, but are not limited to urine, sputum, stool, mucous, saliva, blood, plasma, serum, serum derivatives, bile, phlegm, sweat, amniotic fluid, mammary fluid, and cerebrospinal fluid (CSF), such as lumbar or ventricular CSF. The cell may also be from a fine needle aspirate or biopsied tissue. In particular embodiments, the cells are tumor cells. In other embodiments, the cells are brain cells or embryonic cells.
  • Another aspect of the invention provides methods for analyzing effect of at least one agent on a cell or cellular component. Methods of the invention involve forming a droplet wrapped in an immiscible carrier fluid, in which the droplet includes at least one cell or cellular component and at least one agent, and analyzing the wrapped droplet to determine effect of the agent on the cell or cellular component. Methods of the invention may be used to analyze effect of any agent, or combination of agents, on any cell or combination of cells. In certain embodiments, the cells are mammalian cells, such as human cells or animal cells. In other embodiments, the cells are cells from a human tissue or body fluid. In particular embodiments, the cells are tumor cells. The starting mixture of cells may be either homogeneous (i.e., a mixture including all the same type of cells) or heterogeneous (i.e., a mixture including a plurality of different types of cells).
  • In certain embodiments, methods of the invention are used to analyze specific cellular components, such as a nucleolus, a nucleus, a ribosome, a vesicle, a rough endoplasmic reticulum, a Golgi apparatus, cytoskeleton, a smooth endoplasmic reticulum, a mitochondria, a vacuole, a cytoplasm, a lysosome, or centrioles within centrosome. In particular embodiments, the cellular component is nucleic acid, such as DNA or RNA. Accordingly, cell may be lysed by using a liquid bridge to introduce a droplet containing a lysing agent to the droplet containing the cell. Formation of the mixed droplet mixes the lysing agent with the cell, lysing the cell and releasing the internal cellular components for subsequent analysis. The lysing agent may be a chemical agent, such as surfactants, solvents, or antibiotics.
  • Droplet generation may be accomplished as described above, and droplet generation may be controlled as described above to produce droplets that include only a single cell. Alternatively, droplets may be formed that include a plurality of cells.
  • The agent may be any agent or combination of agents. Exemplary agents are shown in The Merck Index (14th edition. Whitehouse Station, New Jersey, 2009), the contents of which are incorporated by reference herein in their entirety. In particular embodiments, the agent is an anti-cancer agent. Exemplary anti-cancer agents are shown in The Merck Index (14th edition. Whitehouse Station, New Jersey, 2009) and Dorr et al. (Cancer Chemotherapy Handbook, 2d edition, pages 15-34, Appleton & Lange, Connecticut, 1994), the contents of each of which are incorporated by reference herein in their entirety. In particular embodiments, the anti-cancer agent is altretamine, asparaginase, bleomycin, capecitabine, carboplatin, carmustine, cladribine, cisplatin, cyclophosphamide, cytarabine, dacarbazine, actinomycin D, docetaxel, doxorubicin, imatinib, etoposide, fludarabine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, methotrexate, mitomycin, mitotane, mitoxantrone, paclitaxel, topotecan, vinblastine, vincristine, vinorelbine, or combination thereof.
  • In certain embodiments, different concentrations of the same agent is provided to different cells, thus providing an ability to determine an effective dosage level or a toxicity level of an agent.
  • Any device that is capable of forming a sample droplets wrapped in an immiscible carrier fluid may be used with methods of the invention. An exemplary droplet device is a liquid bridge. Wrapped droplet formation using liquid bridges is described above. The sample droplets and the agent droplets may flow through a same channel, and flow may be used to cause the droplets to mix at the liquid bridge to form the mixed wrapped droplet. Alternatively, the sample droplets and the agent droplets may flow through different channels and meet for mixing at the liquid bridge.
  • After droplet mixing, the cell or cells in the mixed wrapped droplet are analyzed to determine the effect of the agent on the cell or cellular component in the droplet. Analyzing may be continuously, periodically or after a specific period of time. Analyzing involves monitoring characteristic analog outcome measures, which may include, but are not limited to: analog size, shape, density, color or opacity; changes in cell number; cell death or proliferation; changes in secreted materials such as cytokines, growth factors, hormones or extracellular matrix components; genetic markers that are up- or down-regulated during the culture period such as genes for receptors, cytokines, integrins, extracellular matrix molecules, or enzymes; and cell-surface molecules including integrins and receptors.
  • One method analyzing the cell or cells includes performing a cell viability and/or proliferative capacity assay. For example, Trypan blue is one of several stains recommended for use in dye exclusion procedures for viable cell counting. This method is based on the principle that Jive cells do not take up certain dyes, whereas dead cells do. Trypan blue is introduced to the cell or cells and the cells are observed for uptake of the stain. A hemocytometer may be used to observe the cell or cells. Methods for performing this assay are well known in the art.
  • Another method for analyzing the cell or cells includes RNA extraction and analysis by reverse transcriptase-polymerase chain reaction (RT-PCR). Cells in the construct are lysed and total RNA extracted with TRIZOL (Life Technologies., Rockville, Md.). Equal amounts (1 μg) of total RNA are subjected to reverse transcription into cDNA at 42° C. for one hour with oligo (dt18) primers. The transcripts are then be amplified by RT-PCR. Sample cDNA are also amplified for housekeeping genes such as rRNA subunit S14 for controls.
  • Another method for analyzing the cell or cells includes cytological-immunocytochemical analysis of cell products. Cells are fixed and stained with either hematoxylin-eosin (H&E) or with monospecific antibodies. Immunostaining for the marker or product of interest is visualized using immunoperoxidase technique with a substrate such as diaminobenzidine which will yield a brownish color. Cell preparations are counterstained with 0.5% toluidine blue.
  • Another method for analyzing the cell or cells includes western blots. Cells may be resuspended in lysis buffer containing protease inhibitors. Protein concentrations may be determined and total cell extracts may be electrophoresed on 7% SDS-polyacrylamide gel overlaid with stacking gel. The proteins are transferred from gel to nitrocellulose paper to immunolocalize the product using monospecific antibodies. To visualize the bands, the membrane blot may be exposed to BioMax Light Film (VWR, NJ).
  • Another method for analyzing the cell or cells includes determination of particular enzyme products. Enzymatic products may be assessed by serially diluting media samples and analyzing enzymatic activity using commercially available kits based on an enzyme linked immunoasssay.
  • Other methods of analyzing the cells include ELISA assays, or microarray technology.
  • Analyzing of the cells may occur while the wrapped droplets are flowing through a channel. For example, for the cell viability assay, the mixed wrapped droplet may flow to a subsequent liquid bridge for an additional mixing step in which the mixed droplet mixes with a droplet of Trypan blue. The droplet now containing the cell(s), agent, and Trypan blue is flowed to a detection device (such as a CCD camera) that images the cells in the droplets as the droplets are flowing through the channel.
  • Alternatively, the droplets may be dispensed to a second vessel prior to analysis. Droplet dispensing may be accomplished as described above. Exemplary vessels include plates (e.g., 96 well or 384 well plates), eppendorf tubes, vials, beakers, flasks, centrifuge tubes, capillary tubes, cryogenic vials, bags, cups, or containers. In particular embodiments, the second vessel is a well plate and the droplets are dispensed into individual wells of the well plate, one droplet per well.
  • In certain embodiments, the droplet including the cell or cellular component is not mixed with an agent. Rather, the unmixed droplet is dispensed to at least one secondary vessel that already includes the agent. For example, droplets are dispensed to individual wells of a well plate in which each well of the plate already includes an agent or combination of agent. After dispensing, the cells are analyzed to assess the effect of the agent or combination of agents on the cell or cellular component.
  • INCORPORATION BY REFERENCE
  • References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, have been made throughout this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes.
  • Equivalents
  • The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

Claims (5)

What is claimed is:
1. A system for analyzing a biological sample, the system comprising:
at least one sample acquisition stage comprising a sample acquisition device for acquiring the biological sample from a sample source;
a droplet generator device for forming a droplet wrapped in an immiscible carrier fluid, wherein the wrapped droplet comprises at least the biological sample and a reagent, the droplet generator configured to receive the biological sample transferred from the sample acquisition device;
a collection vessel for collecting the wrapped sample droplet from the droplet generator, the vessel configured to contain a carrier fluid for receiving and protecting the sample droplet; and
an analysis system for analyzing the wrapped sample droplet and detecting products of a polymerase chain reaction.
2. The system according to claim 1, wherein the droplet generator device is a liquid bridge.
3. The system according to claim 1, further comprising a thermocycler.
4. The system according to claim 1, wherein the sample droplets are dispensed into separate wells of a well plate.
5. The system according to claim 1, wherein the system is configured to dispense the sample droplets as discrete spots on a surface to form an array of droplets.
US15/463,472 2003-09-05 2017-03-20 Methods for culturing and analyzing cells Abandoned US20170320025A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US15/463,472 US20170320025A1 (en) 2006-03-03 2017-03-20 Methods for culturing and analyzing cells
US16/155,411 US10967338B2 (en) 2003-09-05 2018-10-09 Methods of releasing and analyzing cellular components
US17/197,177 US11964244B2 (en) 2009-11-12 2021-03-10 Methods of releasing and analyzing cellular components
US18/615,437 US20240226823A1 (en) 2009-11-12 2024-03-25 Methods and systems of analyzing cellular components

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/366,524 US7622076B2 (en) 2003-09-05 2006-03-03 Microfluidic analysis system
US12/617,286 US20100092987A1 (en) 2003-09-05 2009-11-12 Microfluidic analysis system
US12/683,882 US8968659B2 (en) 2003-09-05 2010-01-07 Sample dispensing
US12/732,769 US9597644B2 (en) 2003-09-05 2010-03-26 Methods for culturing and analyzing cells
US15/463,472 US20170320025A1 (en) 2006-03-03 2017-03-20 Methods for culturing and analyzing cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/732,769 Division US9597644B2 (en) 2003-09-05 2010-03-26 Methods for culturing and analyzing cells

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/155,411 Continuation US10967338B2 (en) 2003-09-05 2018-10-09 Methods of releasing and analyzing cellular components
US18/615,437 Continuation US20240226823A1 (en) 2009-11-12 2024-03-25 Methods and systems of analyzing cellular components

Publications (1)

Publication Number Publication Date
US20170320025A1 true US20170320025A1 (en) 2017-11-09

Family

ID=44673898

Family Applications (5)

Application Number Title Priority Date Filing Date
US12/732,769 Expired - Lifetime US9597644B2 (en) 2003-09-05 2010-03-26 Methods for culturing and analyzing cells
US15/463,472 Abandoned US20170320025A1 (en) 2003-09-05 2017-03-20 Methods for culturing and analyzing cells
US16/155,411 Expired - Lifetime US10967338B2 (en) 2003-09-05 2018-10-09 Methods of releasing and analyzing cellular components
US17/197,177 Active 2030-07-15 US11964244B2 (en) 2009-11-12 2021-03-10 Methods of releasing and analyzing cellular components
US18/615,437 Pending US20240226823A1 (en) 2009-11-12 2024-03-25 Methods and systems of analyzing cellular components

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/732,769 Expired - Lifetime US9597644B2 (en) 2003-09-05 2010-03-26 Methods for culturing and analyzing cells

Family Applications After (3)

Application Number Title Priority Date Filing Date
US16/155,411 Expired - Lifetime US10967338B2 (en) 2003-09-05 2018-10-09 Methods of releasing and analyzing cellular components
US17/197,177 Active 2030-07-15 US11964244B2 (en) 2009-11-12 2021-03-10 Methods of releasing and analyzing cellular components
US18/615,437 Pending US20240226823A1 (en) 2009-11-12 2024-03-25 Methods and systems of analyzing cellular components

Country Status (3)

Country Link
US (5) US9597644B2 (en)
EP (2) EP2553115A4 (en)
WO (1) WO2011119986A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10676786B2 (en) 2003-09-05 2020-06-09 Stokes Bio Ltd. Microfluidic analysis system
US10730051B2 (en) 2006-02-07 2020-08-04 Stokes Bio Ltd. Liquid bridge and system

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597644B2 (en) 2003-09-05 2017-03-21 Stokes Bio Limited Methods for culturing and analyzing cells
US8968659B2 (en) * 2003-09-05 2015-03-03 Stokes Bio Limited Sample dispensing
WO2012139020A1 (en) 2011-04-08 2012-10-11 Stokes Bio Limited Biological detection system and method of use
CN103810364A (en) * 2012-11-09 2014-05-21 中兴通讯股份有限公司 Reliability predicting method and device of laminated packaging reflow soldering process
EP4090328A4 (en) * 2020-01-13 2024-02-14 Fluent Biosciences Inc. Emulsion based drug screening
EP4453246A1 (en) 2021-12-20 2024-10-30 Enumerix, Inc. Detection and digital quantitation of multiple targets

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2572180B1 (en) 1984-10-24 1987-03-20 Eric Marteau D Autry METHOD AND APPARATUS FOR REPAIRING SAMPLES FOR ANALYSIS
US5102517A (en) * 1990-05-23 1992-04-07 Millipore Corporation Capillary wash system
US5641622A (en) 1990-09-13 1997-06-24 Baxter International Inc. Continuous centrifugation process for the separation of biological components from heterogeneous cell populations
US5270183A (en) * 1991-02-08 1993-12-14 Beckman Research Institute Of The City Of Hope Device and method for the automated cycling of solutions between two or more temperatures
DE69429038T2 (en) * 1993-07-28 2002-03-21 Pe Corporation (Ny), Norwalk Device and method for nucleic acid amplification
US6143496A (en) 1997-04-17 2000-11-07 Cytonix Corporation Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly
WO1999041015A1 (en) 1998-02-11 1999-08-19 Institut für Physikalische Hochtechnologie e.V. Miniaturized temperature-zone flow reactor
US6306590B1 (en) * 1998-06-08 2001-10-23 Caliper Technologies Corp. Microfluidic matrix localization apparatus and methods
US6261431B1 (en) * 1998-12-28 2001-07-17 Affymetrix, Inc. Process for microfabrication of an integrated PCR-CE device and products produced by the same
US6294063B1 (en) * 1999-02-12 2001-09-25 Board Of Regents, The University Of Texas System Method and apparatus for programmable fluidic processing
US6193471B1 (en) 1999-06-30 2001-02-27 Perseptive Biosystems, Inc. Pneumatic control of formation and transport of small volume liquid samples
US6524456B1 (en) 1999-08-12 2003-02-25 Ut-Battelle, Llc Microfluidic devices for the controlled manipulation of small volumes
US6355164B1 (en) * 1999-10-29 2002-03-12 Ontogen Corporation Sample collection apparatus and method for multiple channel high throughput purification
US6481453B1 (en) 2000-04-14 2002-11-19 Nanostream, Inc. Microfluidic branch metering systems and methods
WO2001089691A2 (en) 2000-05-24 2001-11-29 Micronics, Inc. Capillaries for fluid movement within microfluidic channels
US20010042712A1 (en) 2000-05-24 2001-11-22 Battrell C. Frederick Microfluidic concentration gradient loop
US20010048637A1 (en) 2000-05-24 2001-12-06 Weigl Bernhard H. Microfluidic system and method
DE10055318A1 (en) 2000-06-09 2001-12-20 Advalytix Ag Process for specific directed manipulation of small amounts of materials on solid body surfaces comprises producing an impulse along the solid body surface, and causing the impulse
EP1317569B1 (en) * 2000-09-14 2009-11-18 Caliper Life Sciences, Inc. Microfluidic devices and methods for performing temperature mediated reactions
AU2001290879A1 (en) 2000-09-15 2002-03-26 California Institute Of Technology Microfabricated crossflow devices and methods
US7378280B2 (en) 2000-11-16 2008-05-27 California Institute Of Technology Apparatus and methods for conducting assays and high throughput screening
CA2450676C (en) 2001-03-09 2010-03-30 Biomicro Systems, Inc. Method and system for microfluidic interfacing to arrays
US7077152B2 (en) 2001-07-07 2006-07-18 Nanostream, Inc. Microfluidic metering systems and methods
AUPR707101A0 (en) 2001-08-16 2001-09-06 Corbett Research Pty Ltd Continuous flow thermal device
US6907895B2 (en) 2001-09-19 2005-06-21 The United States Of America As Represented By The Secretary Of Commerce Method for microfluidic flow manipulation
US20030073089A1 (en) 2001-10-16 2003-04-17 Mauze Ganapati R. Companion cartridge for disposable diagnostic sensing platforms
US7189580B2 (en) 2001-10-19 2007-03-13 Wisconsin Alumni Research Foundation Method of pumping fluid through a microfluidic device
US20030138819A1 (en) 2001-10-26 2003-07-24 Haiqing Gong Method for detecting disease
US20030170698A1 (en) * 2002-01-04 2003-09-11 Peter Gascoyne Droplet-based microfluidic oligonucleotide synthesis engine
FR2839504B1 (en) 2002-05-07 2004-06-18 Commissariat Energie Atomique DEVICE AND METHOD FOR DISPENSING LIQUID PRODUCTS
US7901939B2 (en) 2002-05-09 2011-03-08 University Of Chicago Method for performing crystallization and reactions in pressure-driven fluid plugs
EP2278338B1 (en) * 2002-05-09 2020-08-26 The University of Chicago Device and method for pressure-driven plug transport and reaction
DE10300371B3 (en) 2003-01-06 2004-04-08 Benteler Automobiltechnik Gmbh Production of a coated molded component made from hardened steel used in vehicles comprises locally coating the component after hardening using a coating process which reduces the strength value by the introduction of heat
US7547380B2 (en) * 2003-01-13 2009-06-16 North Carolina State University Droplet transportation devices and methods having a fluid surface
US7041481B2 (en) 2003-03-14 2006-05-09 The Regents Of The University Of California Chemical amplification based on fluid partitioning
GB0315438D0 (en) 2003-07-02 2003-08-06 Univ Manchester Analysis of mixed cell populations
US7767435B2 (en) * 2003-08-25 2010-08-03 University Of Washington Method and device for biochemical detection and analysis of subcellular compartments from a single cell
US9597644B2 (en) 2003-09-05 2017-03-21 Stokes Bio Limited Methods for culturing and analyzing cells
US8968659B2 (en) 2003-09-05 2015-03-03 Stokes Bio Limited Sample dispensing
EP1663497B2 (en) 2003-09-05 2020-03-25 Stokes Bio Limited A microfluidic analysis system
EP1711263A2 (en) * 2003-12-10 2006-10-18 Northeastern University Method for efficient transport of small liquid volumes to, from or within microfluidic devices
US8765454B2 (en) 2004-02-18 2014-07-01 Xiaochuan Zhou Fluidic devices and methods for multiplex chemical and biochemical reactions
KR100552706B1 (en) * 2004-03-12 2006-02-20 삼성전자주식회사 Method and apparatus for nucleic acid amplification
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
WO2006116616A2 (en) 2005-04-26 2006-11-02 Applera Corporation Systems and methods for multiple analyte detection
EP2660482B1 (en) 2005-08-22 2019-08-07 Life Technologies Corporation Vorrichtung, System und Verfahren unter Verwendung von nichtmischbaren Flüssigkeiten mit unterschiedlichen Volumen
US20070134209A1 (en) * 2005-12-12 2007-06-14 Metafluidics, Inc. Cellular encapsulation for self-assembly of engineered tissue
WO2007091230A1 (en) 2006-02-07 2007-08-16 Stokes Bio Limited A microfluidic analysis system
EP1981624B1 (en) 2006-02-07 2011-09-07 Stokes Bio Limited A liquid bridge system and method
DE602007008527D1 (en) 2006-02-07 2010-09-30 Stokes Bio Ltd MICROFLUID NET FOR FORMING A DROPLET AND METHOD
EP2021113A2 (en) 2006-05-11 2009-02-11 Raindance Technologies, Inc. Microfluidic devices
EP2069070B1 (en) 2006-09-28 2013-11-27 Stokes Bio Limited A qpcr analysis apparatus
US8338166B2 (en) * 2007-01-04 2012-12-25 Lawrence Livermore National Security, Llc Sorting, amplification, detection, and identification of nucleic acid subsequences in a complex mixture
US8202686B2 (en) * 2007-03-22 2012-06-19 Advanced Liquid Logic, Inc. Enzyme assays for a droplet actuator
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
EP4047367A1 (en) * 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Method for detecting target analytes with droplet libraries
US20100059120A1 (en) * 2008-09-11 2010-03-11 General Electric Company Microfluidic device and methods for droplet generation and manipulation
US8697011B2 (en) 2009-05-19 2014-04-15 Stokes Bio Limited Sampling device with immiscible fluid supply tube in counter-flow arrangement
US9625454B2 (en) * 2009-09-04 2017-04-18 The Research Foundation For The State University Of New York Rapid and continuous analyte processing in droplet microfluidic devices
WO2011100604A2 (en) 2010-02-12 2011-08-18 Raindance Technologies, Inc. Digital analyte analysis
JP6853667B2 (en) * 2014-04-21 2021-03-31 プレジデント アンド フェローズ オブ ハーバード カレッジ Systems and methods for barcoding nucleic acids

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10676786B2 (en) 2003-09-05 2020-06-09 Stokes Bio Ltd. Microfluidic analysis system
US11807902B2 (en) 2003-09-05 2023-11-07 Stokes Bio Ltd. Microfluidic analysis system
US10730051B2 (en) 2006-02-07 2020-08-04 Stokes Bio Ltd. Liquid bridge and system
US11772096B2 (en) 2006-02-07 2023-10-03 Stokes Bio Ltd. System for processing biological sample

Also Published As

Publication number Publication date
EP2987865A1 (en) 2016-02-24
US20210299619A1 (en) 2021-09-30
WO2011119986A3 (en) 2012-05-18
EP2553115A4 (en) 2013-09-11
EP2553115A2 (en) 2013-02-06
US9597644B2 (en) 2017-03-21
US20240226823A1 (en) 2024-07-11
WO2011119986A2 (en) 2011-09-29
US10967338B2 (en) 2021-04-06
WO2011119986A9 (en) 2012-03-29
US20190105617A1 (en) 2019-04-11
US11964244B2 (en) 2024-04-23
US20100297685A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
US11964244B2 (en) Methods of releasing and analyzing cellular components
EP3248018B1 (en) Devices and systems for molecular barcoding of nucleic acid targets in single cells
US11767500B2 (en) Systems for producing cellular immunotherapeutics and methods of use thereof
US11365404B2 (en) Method for obtaining nucleic acid derived from fetal cell
JP4145938B2 (en) Cell separation chip and cell culture method using the same
US11426729B2 (en) Systems and methods for whole cell analysis
WO2020057531A1 (en) Real-time monitoring of single cell or events
Macaraniag et al. Microfluidic techniques for isolation, formation, and characterization of circulating tumor cells and clusters
CN116157134A (en) Method and apparatus for patient-derived micro-organ spheres
Lin et al. Microfluidic platform for omics analysis on single cells with diverse morphology and size: A review
CN218755788U (en) Apparatus for forming organ balls
JP2006029824A (en) Analysis system of biological material and separation method of biological material
Love Micro-and nanosystems for biotechnology
US20240210290A1 (en) Methods, devices, and kits for purifying and lysing biological particles
US20240159736A1 (en) Method of selecting cells
EP3925702A1 (en) Method and system of producing a library of microorganisms
US20220297126A1 (en) Microfluidic Pipette Aspirators for Large-Scale Analysis of Single Cells, Clusters and Their Sub-Populations
Hoscan Indication of Direction and Magnitude of Flow using DNA Nanotubes
Desalvo Real-time activation profiles of a single T cell arrays following controlled interaction with antigen-presenting cells
WO2023004068A2 (en) Methods, devices, and kits for purifying and lysing biological particles
EP4373616A2 (en) Methods, devices, and kits for purifying and lysing biological particles
Huang et al. Single Cell Analysis on Microfluidic
Ke Microfluidic-based cell assay for biomedical application
Cao Microfluidic Engineering for Ultrasensitive Molecular Analysis of cells

Legal Events

Date Code Title Description
AS Assignment

Owner name: STOKES BIO LTD., IRELAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DAVIES, MARK;DALTON, TARA;REEL/FRAME:046583/0179

Effective date: 20091208

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION